TAVR Beyond Fetal Viability: An Alternative to Preterm Delivery in Symptomatic Severe Aortic Stenosis

Elizabeth Hoover; Tiffany Corlin; Jamie Lohr; Bethany Sabol; Yasuko Yamamura; Katherine Jacobs; S Kimara March; Benjamin Gorbaty; Ganesh Raveendran

doi:10.1016/j.jaccas.2023.102104

TAVR Beyond Fetal Viability: An Alternative to Preterm Delivery in Symptomatic Severe Aortic Stenosis

JACC Case Rep. 2023 Dec 6:27:102104. doi: 10.1016/j.jaccas.2023.102104.

Authors

Elizabeth Hoover¹, Tiffany Corlin¹, Jamie Lohr², Bethany Sabol¹, Yasuko Yamamura¹, Katherine Jacobs¹, S Kimara March³, Benjamin Gorbaty⁴, Ganesh Raveendran³

Affiliations

¹ Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota, USA.
² Division of Pediatric Cardiology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
³ Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
⁴ Division of Cardiac Anesthesia, Department of Anesthesiology, University of Minnesota, Minneapolis, Minnesota, USA.

Abstract

A patient with structural valve degeneration of an aortic bioprosthesis with stenosis stage 3 underwent valve-in-valve transcatheter aortic valve replacement (TAVR) at 29 weeks with improvement. This is the first reported TAVR in the third trimester. TAVR may be an alternative to preterm delivery in cases of symptomatic aortic stenosis.

Keywords: aortic stenosis; bicuspid aortic valve; pregnancy; valve replacement.

Publication types

Case Reports